PCSK9 Inhibitors: A San Diego Cardiologist's Guide to Advanced Cholesterol Management

What a PCSK9 inhibitor actually does

Patients always ask the same thing. What is PCSK9, and why do I need it if I’m already on a statin?

PCSK9 stands for proprotein convertase subtilisin/kexin type 9. Your liver makes it, and I call it a toxin for what it does. Picture LDL cholesterol particles as razor blades circulating in your blood, scraping at otherwise soft, healthy arteries. When you were a kid, your liver carried receptors that worked like garbage disposals in a kitchen sink, grinding up those blades and flushing them. As you age, your body makes PCSK9, which latches onto those receptors and marks them for destruction inside the cell, in compartments called lysosomes. Fewer working disposals, more razor blades circulating, more damage. Some families overproduce PCSK9 for genetic reasons, which is why their cholesterol stays high on a clean diet.

PCSK9 inhibitors unclog the disposals. Three are FDA-approved. Evolocumab (Repatha) and alirocumab (Praluent) are monoclonal antibodies that grab circulating PCSK9 before it reaches a receptor. Inclisiran (Leqvio) uses small interfering RNA to stop your liver from building so much PCSK9 in the first place. Either route, your receptors survive and clear cholesterol the way they did when you were young.

The drop is dramatic. LDL falls 50 to 72 percent depending on the drug and your starting point. Evolocumab averages about 61 percent, inclisiran about 55 percent, alirocumab about 46 percent. I’ve watched patients stuck at 150 mg/dL on maximum statin land at 50 mg/dL. These drugs also cut apolipoprotein B, the protein backbone of the LDL particle, by 43 to 59 percent, and lipoprotein(a), or Lp(a), by 23 to 50 percent. Lp(a) is stubbornly genetic and barely responds to statins or diet, so that last one is a tool we didn’t have. HDL and triglycerides stay where they were. These drugs hit one protein and leave the rest of your biology alone, and that specificity explains their excellent safety profile.

In people with established heart disease, PCSK9 inhibitors cut the risk of another heart attack by 20 to 51 percent and stroke by 19 to 25 percent. Across high-risk populations they reduce cardiovascular events by 15 to 24 percent. Total LDL exposure accumulated over a lifetime is one of the strongest predictors of whether you have a heart attack, so cutting it hard, and earlier, buys years back.

Repatha and Praluent are self-injected every two weeks at home, the way a diabetic injects insulin. The needle hides inside the device and is smaller than the one used to draw your blood. Leqvio runs a schedule many patients prefer. One injection in my office, a second three months later, then one every six months.

Reading your numbers

I recheck your LDL four to eight weeks after we start.

With established cardiovascular disease I want you under 70 mg/dL. For very high risk, meaning multiple heart attacks, diabetes alongside coronary disease, or extensive disease on angiography, I push under 55 mg/dL. Come in at 140 mg/dL on maximum statin and ezetimibe, land at 55 mg/dL, and that’s the 60 percent I expect. Patients with heterozygous familial hypercholesterolemia sometimes start at 250 mg/dL and settle near 80 or 90 mg/dL. Short of target, still an enormous win.

For every 39 mg/dL of LDL reduction, your risk of heart attack, stroke, and cardiovascular death falls about 16 percent. Drop 80 mg/dL and you’re near 33 percent. The cholesterol change happens in weeks. Protection accumulates over years, which is the part patients find hardest.

If your LDL only falls 20 or 30 percent, something is off. Are you taking the injections. Has the drug sat out of the refrigerator long enough to lose potency. Is an undiagnosed thyroid problem driving the number up. I also track apoB, which should fall in proportion to LDL, and Lp(a), which behaves less predictably. Some patients halve their Lp(a) and others get 20 percent.

Once you’re stable I space lipid panels to every three to six months and monitor liver function periodically, though these drugs don’t typically trouble the liver. I repeat an EKG or a stress test if symptoms change, and I order coronary CT angiography or carotid ultrasound when the question calls for it. A coronary calcium score guides how hard to treat someone without symptoms and adds nothing once you have known disease. Good cholesterol control widens your options. Patients stable on optimal medical therapy sometimes stay medical instead of going to stenting or bypass surgery.

Who I put on one

Most of my PCSK9 patients have established atherosclerotic cardiovascular disease and an LDL above 70 mg/dL on maximally tolerated statin therapy. Established means a heart attack, a stroke, peripheral artery disease that needed intervention, or coronary disease documented on angiography. A recent heart attack, especially inside the past year, moves you up my list. Early aggressive lipid lowering after an acute coronary syndrome has strong evidence behind it.

Familial hypercholesterolemia is the other group. Inherit one abnormal gene and your untreated LDL might sit at 200 to 400 mg/dL, and statins rarely close that gap. Inherit two, the homozygous form, and LDL can exceed 600 mg/dL with heart disease showing up in childhood or adolescence. PCSK9 inhibitors are FDA-approved for those patients, who usually need more on top.

Statin intolerance is real, whatever the skeptics say. About 10 to 15 percent of patients get muscle aches, weakness, or other side effects that keep them off an effective dose. Fail several statins at several doses and your maximally tolerated dose is zero, which makes a PCSK9 inhibitor as monotherapy both appropriate and FDA-approved.

The label has moved. In August 2025 evolocumab won expanded approval for high-risk adults without established cardiovascular disease. Alirocumab is approved as monotherapy or combination therapy for primary hyperlipidemia. Insurance has not. Most plans still demand proof that you failed maximum-dose statins and usually ezetimibe, documentation of established cardiovascular disease, or genetic testing confirming familial hypercholesterolemia. I’ll write the letters and file the appeals. First-pass denials are routine, and approvals have taken me anywhere from ten days to four months. Once approved, a specialty pharmacy ships the drug cold and schedules delivery for when you’re home, since it needs refrigeration.

Age alone doesn’t disqualify you, and these work well past 75. At 85 with several serious conditions and a prognosis measured in months, the benefit takes longer to arrive than you have.

When I don’t prescribe one

Pregnancy is an absolute contraindication. We have no safety data in pregnant women, and if you’re planning a pregnancy we stop the drug well ahead of time.

I’m cautious in severe chronic obstructive pulmonary disease and other serious lung conditions. Some data hints at a concern, the evidence isn’t settled, and we talk it through.

I don’t jump to a PCSK9 inhibitor before statins have been pushed, usually with ezetimibe added. If you’re 45, healthy, LDL of 130 mg/dL, no coronary disease, no diabetes, no family history, lifestyle and a statin come first. Same answer if you’re already at goal. An LDL of 45 mg/dL on a statin and ezetimibe with stable coronary disease gives me no reason to add anything.

I hold off when the practical side won’t hold up. Missed appointments and unfilled prescriptions predict missed injections, and these only work on a schedule. Needle phobia that education and practice can’t get past is a real barrier, and so is uncontrolled substance use or psychiatric illness. When insurance denies coverage, no assistance program fits, and the out-of-pocket cost runs $15,000 a year, writing a prescription that never gets filled helps nobody. Bempedoic acid, an oral drug that lowers LDL about 20 to 25 percent, is often the better fit in that corner.

What patients ask me

Can my cholesterol go too low, or hurt my memory? In clinical trials, patients achieved LDL levels below 25 mg/dL without experiencing cognitive decline, depression, or other problems attributed to “too low” cholesterol. Large studies tracked thousands of patients for years and found no increase in neurocognitive events, even at very low LDL. Your brain makes the cholesterol it needs locally. The LDL in your blood is a delivery system, and the excess ends up in artery walls. Tell me if you notice memory trouble and we’ll look into it, though it’s unlikely to be the drug.

What if I miss a dose? Your LDL drifts up slowly. You won’t have a heart attack over one missed injection. Take the next one when you remember and get back on schedule.

Does it replace my statin? Usually not. Statins stabilize plaque and calm inflammation in ways these drugs may not copy, so I keep you on at least a moderate dose unless you genuinely can’t tolerate one. Some patients do better on rosuvastatin, others on atorvastatin. Ezetimibe usually stays too, since it blocks cholesterol absorption in the intestine and adds another 15 to 20 percent of LDL reduction. Statin, ezetimibe, and PCSK9 inhibitor together hit production, absorption, and clearance at once.

Does it cause diabetes? No. Studies looked at glucose control in patients with and without diabetes and found no worsening. Statins carry a small association with new-onset diabetes. These appear neutral.

What about risks we don’t know yet? We’re past a decade of study, with some patients followed more than five years. No cancer signal, no infection signal, nothing unexpected. The common side effect is still an injection site reaction, temporary redness, mild pain, or itching, and rotating between thighs and abdomen keeps it down. If you develop a hard lump under the skin, or increasing pain, warmth, or red streaking, call my office immediately.

Do I take this forever? Plan on it. Your liver keeps making PCSK9, and LDL climbs back toward baseline within weeks to months of stopping. If you’re worn down by the injections or the cost, talk to me before you quit. Switching from evolocumab to inclisiran takes you from twenty-six injections a year to two, and manufacturer assistance programs cover some patients whose copays are impossible.

What these drugs can’t do

They don’t undo damage already done. Scar from an old heart attack stays scar, stented and bypassed arteries stay what they are, and your ejection fraction won’t rise because your cholesterol fell. Plaque regression with aggressive lipid lowering is real and modest, largest in the first year or two, and the lasting benefit comes from stabilizing plaque so it doesn’t rupture.

They don’t fix every lipid problem. Triglycerides above 500 mg/dL need their own treatment, fibrates or prescription omega-3 fatty acids. Lp(a) falls, and if yours is severely elevated the drop may not be enough on its own.

The mortality question is unsettled. Heart attack and stroke reduction is solid. Death from any cause trends in the right direction without reaching statistical certainty in most analyses. One analysis of alirocumab showed a 40 percent mortality reduction, and that needs confirmation in something larger and longer. Data is also thin in children outside familial hypercholesterolemia, in the very elderly, and in severe kidney or liver disease.

And they don’t replace the rest of your care. I want your blood pressure under 130/80 mmHg, hemoglobin A1c under 7 percent if you’re diabetic, 30 minutes of brisk walking most days, a Mediterranean-style diet, 5 to 10 percent weight loss if you’re carrying extra, and no cigarettes, still the single biggest thing you can do for your heart. Most patients with established coronary disease belong on aspirin, and recent stents mean dual antiplatelet therapy for a defined stretch. SGLT2 inhibitors and GLP-1 receptor agonists carry cardiovascular benefit past their glucose effects. Sleep apnea, thyroid disease, and chronic kidney disease each get treated on their own terms. The 2026 cholesterol guideline spells out how hard to escalate and which patients earn the lowest targets. I’ve had patients start one of these and quietly let their diet go, figuring the shot would cover it. It doesn’t.

You won’t feel different on a PCSK9 inhibitor. The benefit is invisible, which makes it hard to stay motivated through injections and copays. Treat each shot as a deposit against an emergency room visit you’d rather not have.

What’s coming

Longer-acting formulations are in development, and oral PCSK9 inhibitors are being studied, though turning an injected protein into a pill is hard. Gene therapy for familial hypercholesterolemia would replace repeat injections with a one-time correction, and it’s years off. Drugs against angiopoietin-like protein 3 (ANGPTL3) and drugs aimed directly at Lp(a) are in late-stage trials. Biosimilars should bring prices down and narrow the gap between what the FDA allows and what insurers cover. Longer follow-up will settle the all-cause mortality question, and growing pediatric data may let us treat genetic high cholesterol early enough to prevent disease.

In my practice patients land in different places on this drug and most of those landings are reasonable. Some take to it right away. Others decide the injections and paperwork outweigh the return. Two things I insist on. Decide with accurate information, and tell me before you stop.

References

Bergeron, N., B. A. Phan, Y. Ding, A. Fong, and R. M. Krauss. “Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition: A New Therapeutic Mechanism for Reducing Cardiovascular Disease Risk.” Circulation 132, no. 17 (2015): 1648-1666.

Rosenson, R. S., R. A. Hegele, S. Fazio, and C. P. Cannon. “The Evolving Future of PCSK9 Inhibitors.” Journal of the American College of Cardiology 72, no. 3 (2018): 314-329.

Imran, T. F., A. A. Khan, P. Has, M. Jacobson, M. Riaz, Z. Tazeen, S. Saleem, et al. “Proprotein Convertase Subtilisn/Kexin Type 9 Inhibitors and Small Interfering RNA Therapy for Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis.” PloS One 18, no. 4 (2023): e0283198.

Katzmann, J. L., C. J. Packard, M. J. Chapman, I. Katzmann, and U. Laufs. “Targeting RNA With Antisense Oligonucleotides and Small Interfering RNA: JACC State-of-the-Art Review.” Journal of the American College of Cardiology 75, no. 11 (2020): 1312-1325.

Huang, Y. T., L. T. Ho, H. Y. Hsu, Y. K. Tu, and K. L. Chien. “Efficacy and Safety of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors as Adjuvant Treatments for Patients With Hypercholesterolemia Treated With Statin: A Systematic Review and Network Meta-Analysis.” Frontiers in Pharmacology 13 (2022): 832614.

Bai, J., L. L. Gong, Q. F. Li, and Z. H. Wang. “Long-Term Efficacy and Safety of Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibodies: A Meta-Analysis of 11 Randomized Controlled Trials.” Journal of Clinical Lipidology 12, no. 6 (2018): 1459-1467.

Ruhela, N., A. Singla, Y. V. Trivedi, V. Bhardwaj, P. Sharma, and M. Bansal. “Advancements in Lipid-Lowering Therapy: The Role of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Beyond in Cardiovascular Risk Reduction.” Coronary Artery Disease 36, no. 1 (2025): 57-66.

AlTurki, A., M. Marafi, A. Dawas, N. Deyell, R. Proietti, V. Thanassoulis, and M. Cortes. “Meta-Analysis of Randomized Controlled Trials Assessing the Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies on Mortality and Cardiovascular Outcomes.” The American Journal of Cardiology 124, no. 12 (2019): 1869-1875.

Turgeon, R. D., and G. J. Pearson. “Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors for Reduction of Cardiovascular Events.” American Journal of Health-System Pharmacy 75, no. 23 (2018): 1898-1905.

Pamporis, K., P. Karakasis, and D. Tsiachris. “Safety and Effectiveness of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition: An Updated Review.” Current Opinion in Lipidology 36, no. 1 (2025): 22-30.

Jia, X., M. Al Rifai, A. Saeed, C. M. Ballantyne, and S. S. Virani. “PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance.” Vascular Health and Risk Management 18 (2022): 555-566.